TITLE

Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression

PUB. DATE
December 2009
SOURCE
International Journal of Advances in Rheumatology;2009, Vol. 7 Issue 4, p134
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This meta-analysis of the most recent studies comparing cyclophosphamide with mycophenolate mofetil (MMF) for the treatment of lupus nephritis suggests that MMF offers similar efficacy to cyclophosphamide, with less toxicity.
ACCESSION #
48381933

 

Related Articles

  • TREATMENT OF PROLIFERATIVE LUPUS NEPHRITIS WITH CYCLOPHOSPHAMIDE. Munteanu, Andreea; Caraba, A.; Romosan, I. // Annals of the Romanian Society for Cell Biology;2012, Vol. 17 Issue 2, p153 

    Lupus nephritis (LN) is one of the most severe and common manifestations of SLE, being a major cause of morbidity and death. Renal impairment plays a determinant role in the development of the disease, renal failure being one of the main death causes in SLE. The incidence of LN varies according...

  • Update on the management of lupus nephritis. Marinaki, Smaragdi; Skalioti, Chryssanthi; Boletis, Ioannis N. // BANTAO Journal;2014, Vol. 12 Issue 1, p10 

    The treatment of lupus nephritis still represents a therapeutic challenge for the clinician. Besides early recognition, appropriate guiding by the histologic classification at presentation as well as at relapsing disease, is essential. The most severe proliferative and mixed forms require...

  • Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A. Závada, J; Pešičková, S Sinikka; Ryšavá, R; Horák, P; Hrnčíř, Z; Lukáč, J; Rovenský, J; Vítová, J; Havrda, M; Rychlík, I; Böhmova, J; Vlasáková, V; Slatinská, J; Zadražil, J; Olejárová, M; Tegzova, D; Tesar, V // Lupus;Jan2014, Vol. 23 Issue 1, p69 

    The article examines the extended follow-up of the CYLOFA-LUNE randomized controlled trial that compares two sequential proliferative lupus nephritis induction and maintenance treatments based on cyclosporine A (CyA) or cyclophosphamide (CPH). The study shows no difference on the end-stage renal...

  • Lupus nephropathy in New Zealand F1 hybrid mice treated by (-) 15-deoxyspergualin. Okubo, Michichito; Inoue, Keicchi; Umetani, Naoki; Sato, Naoyuki; Kamata, Kouju; Masaki, Yoshihiko; Uchiyama, Takehiko; Xiao-Jie Yan; Aoyagi, Takaaki; Shirai, Toshikazu // Kidney International;Oct1988, Vol. 34 Issue 4, p467 

    The effect of (-)15-deoxyspergualin (15-dsp), a new immunosuppressant which was originally separated from the culture filtrate of a strain of Bacillus laterosporus, was evaluated in this study. Various doses of 15-dsp were subcutaneously administered to New Zealand black/white F1 hybrid mice...

  • Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Kanda, H.; Kubo, K.; Tateishi, S.; Sato, K.; Yonezumi, A.; Yamamoto, K.; Mimura, T. // Lupus;2005, Vol. 14 Issue 4, p288 

    Recent immunosuppressive treatments for lupus nephritis have improved renal survival rate, however, there still exists lupus nephritis refractory to these treatments. Angiotensin receptor blockers (ARBs)are known not only to decrease blood pressure but also to have an independent renoprotecting...

  • Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Yumura, W.; Suganuma, S.; Uchida, K.; Moriyama, T.; Otsubo, S.; Takei, T.; Naito, M.; Koike, M.; Nitta, K.; Nihei, H. // Clinical Nephrology;2005, Vol. 64 Issue 1, p28 

    Aim: Mizoribine (MZR) is a purine antimetabolic immunosuppressant agent that has few little severe adverse events. We studied whether maintenance therapy with MZR and prednisolone (PSL) in severe proliferative lupus nephritis patients could improve immunity, reduce proteinuria, prevent renal...

  • Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lee, Y. H.; Woo, J-H.; Choi, S. J.; Ji, J. D.; Song, G. G. // Lupus;May2010, Vol. 19 Issue 6, p703 

    The aim of this study was to assess the efficacies and toxicities of immunosuppressive treatments for lupus nephritis (LN) versus cyclophosphamide (CYC). A meta-analysis was performed to determine treatment efficacy and toxicity outcomes between mycophenolate mofetil (MMF) and CYC induction...

  • Mycophenylate mofetil: what role in the treatment of lupus? Dooley, M. A. // Lupus;2006, Vol. 15 Issue 3, p179 

    Improved patient survival following lupus nephritis with the institution of corticosteroids, immunosuppressants and renal replacement therapy allows greater emphasis on long-term management issues. In particular, the recent focus has been on therapies to treat nephritis with fewer adverse...

  • 343. Antiproteinuric treatment reduces lesions of lupus nephritis. Hill, G.S.; Delahousse, M.; Nochy, D. // Kidney;May/Jun2002, Vol. 11 Issue 3, p113 

    Provides information on a study which investigated proteinuria and tubulointerstitial lesions in lupus nephritis. Methodology; Results; Conclusion.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics